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ABSTRACT 
The specific goals of this study are to determine trends in the usage and comparison of clinical patterns of antidepressant treatment modality in a 
tertiary hospital between year 2009-2011. We retrospectively reviewed prescription records in the Outpatient Pharmacy Department (OPD) of a 
tertiary hospital in central Malaysia from 2009 to 2011. About 3000 prescriptions, containing at least one anti-depressant drug, were systematically 
sampled and evaluated. Malay patients had a decreasing trend of 3% in anti-depressant usage over the study. Escitaloprom (SSRI) group was found 
to be the most widely utilized antidepressant with a steady increase of 9% while usage of Fluvoxamine was found to show a decreasing trend over 
the three years. The overall pattern profoundly favoured monotherapy modality rather than combination therapy among practitioners. This study 
also found an increasing pattern in the use of antidepressants with antianxiety and antipsychotic. In general, this study has contributed additional 
information regarding the prescribing pattern of anti-depressants in Malaysia at the current moment. 
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INTRODUCTION 
Depression is rapidly becoming a major global burden in the recent 
years with many victims becoming more vulnerable to major social 
and environmental factors1. According to the World Health 
Organisation (WHO) and the World Bank, depression is the fourth 
most disabling disease in the world. It is perceived to be an illness 
that potentially can overtake chronic diseases such hypertension 
and diabetes 2, 3. In this context, anti-depressants play a major role in 
managing depression and are considered as the first line therapy for 
depression management in many countries. Over the years 
antidepressant prescribing patterns have undergone revolution with 
rational prescribing practice being implemented globally, resulting 
in conventional drugs like tricyclic antidepressant (TCA) and mono-
amine oxidase inhibitors (MAOI) being gradually replaced by 
selective serotonin reuptake inhibitors (SSRI), serotonin–
norepinephrine reuptake inhibitor (SNRI) and novel 
antidepressants.   
In Malaysia, almost 10% of the population are believed to be 
suffering from this disease and practitioners rely heavily on the use 
of anti-depressant in disease management 4. However, there has 
been very little studies involving anti-depressant usage in Malaysia. 
Thus, an investigation into the prescribing pattern of anti-
depressants is warranted to determine the changes that have 
occurred in this practice. To our knowledge, this study is a pioneer 
study aimed at assessing the use of different classes of 
antidepressants in Malaysia by comparing the clinical patterns of 
anti-depressant medication treatment in a tertiary hospital between 
the years 2009-2011.  
METHOD 
This study was carried out as a retrospective study reviewing 3000 
prescriptions from the Outpatient Pharmacy Department (OPD) of 
Hospital Klang , Selangor. Permission to conduct the study was 
obtained from the hospital ethics committees. Targeted data for the 
study were prescriptions available at the OPD from the year 2009 to 
2011 containing one or more antidepressant drugs. Prescriptions 
from the OPD which fulfill these criteria will be included in the 
study: 
a) Prescriptions used from the year 2009 to 2011 
b) Has one or more anti-depressant given for indication of 
depression 
A randomized systematic sampling method will be used, whereby 
anti-depressant prescriptions that satisfy the study criteria  will  be  
 
identified from the main study population (sampling frame). 
Subsequently, for every 2 anti-depressant prescriptions fulfilling the 
criteria, one will be randomly picked to be utilized in the study 5. 
Data Collection  
A data collection form was used to compile information from eligible 
prescriptions. Documentation of the data included demographic 
characteristics, pattern of drug use, duration) and trends in 
treatment modality (monotherapy versus combination therapy and 
types of combination). 
Statistical Analysis  
The data collected will be analyzed using SPSS version 12.0 (SPSS 
Inc., Chicago, IL) and Microsoft Excel. Continuous data were 
presented as mean values + standard deviation while categorical 
data were presented as percentages. Descriptive statistics were used 
to analyze the data and results were represented in tabular form or 
graphically. Cross tabulation using Chi-square tests were used to 
evaluate the pattern of drug use. The level of significance (p-value) 
was set at = 0.05. 
RESULTS 
A total of 3000 prescriptions were randomly selected for this study 
averaging around 1000 prescriptions for each year. As shown in 
Table 1, male and female had almost equal incidences of anti-
depressant prescribing. Looking into ethnic differences, the Malays 
has the highest proportion of receiving depression treatment though 
the percentage has reduced from 38.9% in 2009 to 35.3% in 2011, 
whereas the depression medications prescribed among the Chinese 
have increased slightly from 2009 to 2010 (2.5%)  and then small 
reduction was observed in 2011 (0.08%). Meanwhile, the number of 
depression prescriptions among the Indians reduced from 2009 to 
2010 and then increased slightly in year 2011. Table-1 provides a 
summary of the demographic data obtained from the prescriptions 
The prescribing pattern of anti-depressants over the 3-year study 
period is shown in Table-2. SSRI is the most widely used class of 
anti-depressant drugs in this study.  Fluvoxamine turned out to be 
the most frequently prescribed antidepressant and sertraline ranked 
second in the hierarchy of prescriptions followed by venlafaxine 
from SNRI class. But these SSRIs were upstaged by escitalopram in 
the study duration. Venlafaxine however recorded a decreasing 
trend over the study period. Therapeutic pattern (monotherapy vs 
combination therapy) in the use of depression is showed in Figure 2. 
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Table 1: Demographic characteristic of outpatients’ prescriptions for anti-depressant therapy at a tertiary hospital in peninsular 
Malaysia (2009-2011) 
 
Characteristic 2009 2010 2011 p-value 
















Mean 42.41 43.21 44.17 <0.05 






























S = Significant; NS=Non significant 
 
Figure 1: Trends in monotherapy of anti-depressant agents for 
outpatients receiving depression prescriptions at a tertiary hospital 
in Peninsular Malaysia (2009-2011) 
Generally, combination therapy is not practiced in Malaysia as we 
can see the number of prescriptions being very low while 
monotherapy is strongly favoured registering high number of 
prescriptions each year. The monotherapy category was initially 
largely dominated by fluvoxamine in 2009 but then a significant 
downward trend was observed where the usage dropped from 
37.7% in 2009 to 20.9% in 2011. However, this drift was in contrast 
to the pattern seen in escitalopram where a tremendous increase 
can be seen, about 9% over the 2 years period as shown in Figure 1.  
Monotherapy antidepressant drugs are concomitantly prescribed 
with antianxiety and anti-pscyhotic drugs, which is displayed in 
Figure 3 and Figure 4. A tremendous increase in co-precribing anti-
depressant drug with clonazepam was recorded, with increases 
amounting to 19% from the year 2009 till 2011. On the other hand, 
lorazepam which was initally the highest anti-anxiety drug 
prescribed  illustrated a downward trend from 13.9% in 2009 to 
5.4% in 2011. Diazepam also showed a drop in usage ,around 2.5%,  
although it was not as popular as the other anti-anxiety drugs. 
Similarly, Figure 4 shows that risperidone and sulpride are the most 
common anti-psychotics prescribed together with anti-depressant 
drugs. There was a continuous increase in usage of risperidone with 
anti-depressants from year 2009 to 2011 while sulpride had 
fluctuating usage over the years. 
Table 2: Trends in the usage of anti-depressants among outpatients receiving antidepressants prescriptions at a tertiary hospital in 
Peninsular Malaysia (2009-2011) 
 
Agent 2009 2010 2011 p-value 
Selective Serotonin 
Receptor Inhibitor (SSRI) 























Reuptake Inhibitor (SNRI) 





39 (3.9%)  
TricyclicAntidepressants 
(TCA) 















S = Significant; NS=Non significant
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Figure 2: Trends in therapy modalities for anti-depressants 
amongst outpatients receiving depression prescriptions at a 
tertiary hospital in peninsular Malaysia (2009-2011) 
Figure 3 : Trends in monotherapy of anti-depressants with anti-
anxiety agents for outpatients receiving depression 
prescriptions at a tertiary hospital in Peninsular Malaysia 
(2009-2011) 
 
Figure 4: Trends in monotherapy of anti-depressants with anti-
psychotic and anti-manic agents for outpatients receiving 
depression prescriptions at a tertiary hospital in Peninsular 
Malaysia (2009-2011) 
DISCUSSION 
This was a retrospective study through prescriptions evaluation, 
detailing on the epidemiology of depression in a tertiary hospital in 
Malaysia. Three main groups of antidepressant drugs comprising of 
the (SSRI), (SNRI) and (TCA) were identified and pattern of their 
usage were evaluated. Results of the demographic data reveal that 
ethnic differences occur in the prevalence of anti-depressant 
prescribing whereby there is a continuous decrease in among Malay 
patients and increase in the number of Chinese patients. This can be 
explained by the vulnerability of the Chinese community towards 
stress and mental health problems. A study by Tahir Mehmood Khan 
et al 6 revealed that the Chinese in Malaysia display high priority in 
matters relating to emotions and due to increase of divorce rate and 
relationship breakdown among Chinese, a higher risk of depression 
is inevitable. 
This study revealed that the primary anti-depressants used by 
practitioners in Malaysia are SSRI as regulated by the Clinical 
Practice Guidelines 2007 7, 8. As shown by Figure 1, the findings also 
imply that escitalopram is the most widely used SSRI agent with a 
gradual increase from 2009 to 2011. This is an interesting finding as 
escitalopram was not a very popular drug initially. But recent 
studies have shown that escitalopram has the potential to deliver 
superior benefits compared to traditional SSRI 9, 10 and might have 
caused the surge in usage.  Venlafaxine, a SNRI agent, proved to be 
another widely used anti-depressant although its use illustrates a 
downward trend while TCA seems to have regained popularity and 
has an increasing trend by the year 2011. Practitioners in Malaysia 
may have reduced venlafaxine use and turned towards TCA due to 
the adverse effects and the high cost of venlafaxine. SNRI has a 
higher affinity towards serotonin toxicity and can lead to tolerability 
issues with patients along with increased health cost burden 11, 12. 
Generally in Malaysia, monotherapy of antidepressant is the main 
mode of therapy utilized by practitioners in tertiary hospital 
nationwide. Figure 2 suggests a similar trend was discovered in this 
study that shows combination therapy is very rarely used practice. 
According to JK Trivedi (2011) dual or triple medications for is 
associated with higher frequency of adverse effects without any 
additional benefits 13 .Rather than utilizing multiple anti-
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depressants, physicians in Malaysia prefer to combine 
benzodiazepines (anti-anxiety) with anti-depressants for optimum 
health outcome. The administration of benzodiazepines in suicidal, 
anxious or agitated patients with depression is common 
international practice 14, 15, and 16. Furukawa et al. (2001) analysed 
nine studies with a total of 679 patients to determine benefits of 
adding benzodiazepines to antidepressants in patients with major 
depression. The intent-to-treat analysis (with drop-outs assigned the 
least favourable outcome) showed that patients allocated to the 
combination therapy were less likely to drop out of study and were 
more likely to show improvement of depression15. 
 Based on our finding in Figure 3, clonazepam is the most used 
widely benzodiazepine agent registering an increase of 15% each 
year compared to lorazepam and alprazolam. This is probably due to 
the augmentation effect demonstrated by clonazepam when 
combined with SSRI. Clonazepam has potential to increase the 
effects of SSRI and also partially suppress the adverse effects of SSRI 
15, 16, and 17. Although these properties are minimally present in 
lorazepam and alprazolam, but clonazepam exhibits the highest 
degree of these beneficial effects. Figure 4 shows the analysis on 
usage of anti depressants with antipsychotic drugs and anti-manic 
drugs. Risperidone shows a gradual increase from year 2009 to 2011 
which implies that practitioners have found beneficial effects 
utilizing this agent for depression management. A study done by 
Ostroff & Nelson reported on eight patients with non-psychotic 
depression who failed to respond to an SSRI, but responded when 
risperidone was added. Similarly, practitioners believe that patient 
also benefit from addition of lithium to   anti-depressant therapy. 
This is due to the increase in serotonin (5-HT) neurotransmission, 
possibly through a synergistic action of lithium and the 
antidepressant on brain 5-HT pathways. But lithium is reserved 
primarily for refractory depression, hence the low number of usage 
shown in Figure 4. 
CONCLUSION 
Our study shows that the appearance of novel therapeutic agents 
and new clinical evidences in the management of depression has 
initiated a revolution in anti-depressant drugs utilization among 
practitioners. SSRIs are widely acknowledged to have fewer side 
effects and a more tolerable pharmacological profile making them 
more ‘user friendly’. Escitaloprom is gradually replacing 
Fluvoxamine as the first line therapy among the physicians in 
Malaysia. The prescribing mode of therapy still remains favourable 
for monotherapy. Studying the prescription patterns can help the 
practitioners to adopt rational prescribing practice in a better 
manner throughout Malaysia. 
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